Almirall : announces Ron Menezes as new President & General Manager at Aqua Pharmaceuticals

Barcelona, 22 August 2017

Almirall S.A. announced the appointment of Ron Menezes as the new President & General Manager of Aqua Pharmaceuticals. He will be joining Aqua on September and will bring with him broad experience in the field of Dermatology in the US, the largest and most important market in the world.

According to Eduardo Sanchiz, Almirall's CEO, 'we are very pleased to announce the appointment of Ron Menezes as the new President & GM of Aqua Pharmaceuticals reporting to Alfonso Ugarte, Executive Vice-president of Commercial Strategy. Ron's incorporation and the experience he brings in dermatology represent a clear and undeniable opportunity to further strengthen this organization. Almirall continues to consider Aqua as a very important platform in the US market to support existing and new products'.

Most recently Ron was at Depomed Pharmaceuticals serving as Vice President of Sales and Sales Operations, Pain and CNS Portfolio. Prior to that, Ron had a very successful career at Allergan where he started as National Sales Director of Medical Dermatology. Later, and after showing outstanding results, he was promoted to Vice President Sales and Marketing, Medical Dermatology and, finally, and he was given additional responsibilities leading both the Medical Dermatology and SkinMedica team. Before Allergan, Ron held leadership positions at Abbott, Astellas and Pfizer.

Ron has a B.S. International Business from Brigham Young University and a Health Care Management graduate certificate from the University of Utah.

He will be replacing Ted White, who has been President and General Manager of the company since January 2016. Almirall would like to sincerely thank Ted White, for his efforts and contribution during the last 7 years that he has worked at Aqua Pharmaceuticals. His contribution has been key to achieve the success that Aqua has had in the past.

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programmes including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.

Founded in 1943, with headquarters in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the long-standing commitment of its major shareholders. In 2016, its revenues totalled 859.3 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

For more information, please visit www.almirall.com.

Disclaimer

This document only includes summary information and does not intend to break down the economic figures included herein. The facts and figures contained herein, other than those referring to past events, are 'forward-looking statements'. These 'forward-looking statements' are based on currently available information and on best estimates and assumptions believed to be reasonable by the companies. These 'forward-looking statements' involve risks and uncertainties beyond the companies' control. Therefore, actual results may differ materially from those stated by such 'forward-looking statements'. The companies expressly disclaim any obligation to review or update any 'forward-looking statements' or targets contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based, unless so required by applicable law.